TCGA-C8-A1HM-01A-12R-A137-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 12
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.660
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.570
- ALLOGRAFT_REJECTION+0.520
- MTORC1_SIGNALING+0.440
- MYC_TARGETS_V1+0.400
- IL6_JAK_STAT3_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.320
- MYC_TARGETS_V2+0.320
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.500
- MYOGENESIS-0.460
- HEDGEHOG_SIGNALING-0.430
- NOTCH_SIGNALING-0.420
- APICAL_JUNCTION-0.390
- TGF_BETA_SIGNALING-0.390
- UV_RESPONSE_DN-0.350
- COAGULATION-0.290
- WNT_BETA_CATENIN_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518156 | — | D | 0.932 |
| 2 | SRR8518289 | — | E | 0.914 |
| 3 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.912 |
| 4 | SRR25043627 | — | — | 0.905 |
| 5 | TCGA-18-3416-01A-01R-0980-07 | — | cohortSQ2 | 0.895 |
| 6 | SRR1313144 | — | D | 0.890 |
| 7 | GSM6454734 | — | D | 0.889 |
| 8 | SRR1313135 | — | C | 0.889 |
| 9 | SRR5088813 | — | — | 0.888 |
| 10 | C3L-04757 | — | cohortA1 | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.660 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |